Please wait. Loading...
 

Δημοσιεύσεις

Κατευθυντήριες Οδηγίες

  • Κατεβάστε σε μορφή pdf τις Αναθεωρημένες Κατευθυντήριες Οδηγίες της Ευρωπαικής Εταιρίας Υπέρτασης - 2009.
     
  • American Heart Association Learn and Live 2009 STEMI and PCI Focused Update
     

Newsletter

Εγγραφείτε στο Newsletter μας και μάθετε πρώτοι τα νέα και τις επερχόμενες επιστημονικές εκδηλώσεις της εταιρίας.

  •  

Με την ευγενική χορηγία:

CHIESI HELLAS


SANOFI

Should blockers remain first choice in the treatment of
primary hypertension? A meta-analysis

Lars Hjalmar Lindholm, Bo Carlberg, Ola Samuelsson

Summary

Background: _ blockers have been used widely in the treatment of hypertension and are recommended as first-line drugs in hypertension guidelines. However, a preliminary analysis has shown that atenolol is not very effective in hypertension. We aim to substantially enlarge the data on atenolol and analyse the effect of different _ blockers.

Methods: The Cochrane Library and PubMed were searched for _ blocker treatment in patients with primary hypertension. Data were then entered into the Cochrane Collaboration Review Manager package and were summarised in meta-analyses. 13 randomised controlled trials (n=105 951) were included in a meta-analysis comparing treatment with _ blockers with other antihypertensive drugs. Seven studies (n=27 433) were included in a comparison of _ blockers and placebo or no treatment.

Findings: The relative risk of stroke was 16% higher for _ blockers (95% CI 4-30%) than for other drugs. There was no difference for myocardial infarction. When the effect of _ blockers was compared with that of placebo or no treatment, the relative risk of stroke was reduced by 19% for all _ blockers (7-29%), about half that expected from previous hypertension trials. There was no difference for myocardial infarction or mortality.

Interpretation: In comparison with other antihypertensive drugs, the effect of _ blockers is less than optimum, with a raised risk of stroke. Hence, we believe that _ blockers should not remain first choice in the treatment of primary hypertension and should not be used as reference drugs in future randomised controlled trials of hypertension.

Κατεβάστε την ολοκληρωμένη δημοσίευση σε μορφή pdf.

 

 

© 2010-2014 Hellenic Society of Cardiovascular Prevention. All rights reserved.